Intravenous secretin for autism spectrum disorder
KW Williams, JJ Wray, DM Wheeler
Cochrane Database of Systematic Reviews | WILEY | Published : 2005
Internal sourcesSmall Grants Scheme of the Children's Hospital at Westmead, Australia.External sourcesFinancial Markets Foundation for Children, Australia.John A Wray - was involved in two trials included within this review (Wray; Levy 2003). Dr Wray has declared he delivered a previous testimony for inclusion of risperidone for children with autism on Australia's Public Medicines Prescription Benefit Scheme. Airfares and accommodation were paid for by Janssen Pharmaceutical.The authors would like to thank those trialists who provided us with information and debate about secretin. We thank Drs Julian Higgins, Alex Sutton, Jon Deeks, Jenny Peat and Andrew Hayen for their advice and assistance with methods and meta-analysis. We commend the tireless efforts of the Cochrane Developmental, Psychosocial and Learning Problems Group for their help with literature searching, review and editing, in particular the support of Dr Jane Dennis. Danielle Wheeler was funded by the Small Grants Scheme of The Children's Hospital at Westmead and the Financial Markets Foundation for Children.